

SUMMARY PRODUCT CHARACTERISTICS

1. Name of the medicinal product

PEPGEL PLUS SUSPENSION

2. Qualitative and quantitative composition

Each 5ml Contains:

Simethicone Emulsion USP

Equivalent to Simethicone 25mg

Magnesium Hydroxide USP 200 mg

Dried Aluminium Hydroxide gel USP 225.0 mg

Eq to Aluminium Hydroxide 172.125 mg

Liquid Sorbitol(Non-crystallising)BP q.s

Colour: Erythrosine

For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Oral dosage form (Oral Suspension)

Pink coloured, syrupy suspension with peppermint odour.

4. Clinical particulars

4.1 Therapeutic indications

The symptomatic relief of:

1. Dyspepsia.
2. Heartburn.
3. Flatulence.

4.2 Posology and method of administration

For oral administration:

Adults

5-10ml taken 20 minutes to 1 hour after meals and at bedtime or as required.

Children

As an appropriate proportion of the adult dose.

Children under 5 years

Maximum of 5ml t.d.s.

Elderly

The normal adult dose is appropriate.

4.3 Contraindications

Should not be used in patients who are hypersensitive to any of the active substances or excipients, are severely debilitated or suffering from kidney failure, or hypophosphataemia.

4.4 Special warnings and precautions for use

Aluminium hydroxide may cause constipation and magnesium salts overdose may cause hypomotility of the bowel; large doses of this product may trigger or aggravate intestinal

obstruction and ileus in patients at higher risk such as those with renal impairment, or the elderly.

Aluminium hydroxide is not well absorbed from the gastrointestinal tract, and systemic effects are therefore rare in patients with normal renal function. However, excessive doses or long-term use, or even normal doses in patients with low-phosphorous diets, may lead to phosphate depletion (due to aluminium-phosphate binding) accompanied by increased bone resorption and hypercalciuria with the risk of osteomalacia. Medical advice is recommended in case of long-term use or in patients at risk of phosphate depletion.

In patients with renal impairment, plasma levels of both aluminium and magnesium increase. In these patients, a long-term exposure to high doses of aluminium and magnesium salts may lead to encephalopathy, dementia, microcytic anemia or worsen dialysis-induced osteomalacia.

Aluminium hydroxide may be unsafe in patients with porphyria undergoing hemodialysis. The prolonged use of antacids in patients with renal failure should be avoided.

Paediatric population

In young children the use of magnesium hydroxide can produce a hypermagnesemia, especially if they present renal impairment or dehydration.

4.5 Interaction with other medicinal products and other forms of interaction

Pepgel Plus should not be taken simultaneously with other medicines as they may interfere with their absorption if taken within 1 hour.

Aluminium-containing antacids may prevent the proper absorption of drugs notably H₂ antagonists, atenolol, bisphosphonates, cefdinir, cefpodoxime, chloroquine, chlorpromazine, ciprofloxacin, cyclines, dasatinib monohydrate, dexamethasone, diflunisal, digoxin, eltrombopag olamine, elvitegravir, ethambutol, fluoroquinolones, glucocorticoids, hydroxychloroquine, indomethacin, iron salts, isoniazid, ketoconazole, levothyroxine, lincosamides, metoprolol, nilotinib, phenothiazine neuroleptics, penicillamine, propranolol, raltegravir potassium, rifampicin, rilpivirine, riociguat, rosuvastatin, sodium fluoride, antiviral treatment combination of tenofovir alafenamide fumarate/emtricitabine/bictegravir sodium, tetracyclines, and vitamins.

With the integrase inhibitors (dolutegravir, raltegravir, bictegravir) the combination should be avoided (please refer to their SmPC for dose recommendations).

As a precaution, staggering the administration times of any orally administered drug and the antacid by at least 2 hours (4 hours for the fluoroquinolones).

Levothyroxine may also bind to simeticone which may delay or reduce the absorption of levothyroxine.

Polystyrene sulphonate

Caution is advised when used concomitantly with polystyrene sulphonate due to the potential risks of reduced effectiveness of the resin in binding potassium, of metabolic alkalosis in patients with renal failure (reported with aluminium hydroxide and magnesium hydroxide), and of intestinal obstruction (reported with aluminium hydroxide).

Quinidine:

Concomitant use of aluminium products with quinidines may increase the serum levels of quinidine and lead to quinidine overdose.

Tetracycline:

Because of the aluminium content, Pepgel Plus should not be concomitantly administered with tetracycline-containing antibiotics or any tetracycline salts.

Citrates:

Aluminium hydroxide and citrates may result in increased aluminium levels, especially in patients with renal impairment.

Urine alkalinisation secondary to administration of magnesium hydroxide may modify excretion of some drugs; thus, increased excretion of salicylates has been seen.

4.6 Fertility, pregnancy and lactation

The safety of Peggel Plus (Suspension) in pregnancy has not been established.

Pregnancy:

There are no available data on Peggel Plus use in pregnant women. No conclusions can be drawn regarding whether or not Peggel Plus is safe for use during pregnancy. Peggel Plus should be used during pregnancy only if the potential benefits to the mother outweigh the potential risks, including those to the fetus.

Lactation:

Because of the limited maternal absorption, when used as recommended, minimal amounts, if any, of aluminium hydroxide and magnesium salt combinations are expected to be excreted into breast milk.

Simeticone is not absorbed from the gastrointestinal tract.

No effect on the breastfed newborn/infant are anticipated since the systemic exposure of the breast-feeding woman to aluminium hydroxide, magnesium hydroxide and simeticone is negligible.

4.7 Effects on ability to drive and use machines

None stated.

4.8 Undesirable effects

The following CIOMS frequency rating is used, when applicable:

Very common ($\geq 1/10$), common ($\geq 1/100$ to $<1/10$), uncommon ($\geq 1/1,000$ to $<1/100$), rare ($\geq 1/10,000$ to $<1/1,000$), very rare ($<1/10,000$), not known (cannot be estimated from available data).

Immune system disorders

Frequency not known: hypersensitivity reactions, such as pruritus, urticaria, angioedema and anaphylactic reactions

Gastrointestinal disorders

Gastrointestinal side-effects are uncommon.

Uncommon: diarrhoea or constipation

Frequency not known: Abdominal pain

Injury, poisoning and procedural complications:

Frequency not known:

Hyperaluminemia (related to Aluminium component).

Metabolism and nutrition disorders

Very rare: Hypermagnesemia, including observations after prolonged administration of magnesium hydroxide to patients with renal impairment

Frequency not known:

Hyperaluminemia

Hypophosphatemia, in prolonged use or at high doses or even normal doses of the product in patients with low-phosphorus diets which may result in increased bone resorption
hypercalciuria, osteomalacia

Reporting of suspected adverse reactions

Reporting of suspected adverse reactions: Healthcare professionals are requested to report any suspected adverse reactions to the National Regulatory Agents

4.9 Overdose

Serious symptoms are unlikely following overdosage.

Reported symptoms of acute overdose with aluminium hydroxide and magnesium salts combination include diarrhoea, abdominal pain, vomiting.

Large doses of this product may trigger or aggravate intestinal obstruction and ileus in patients at risk

Aluminium and magnesium are eliminated through urinary route; treatment of acute overdose consists of administration of IV Calcium Gluconate, rehydration and forced diuresis. In case of renal function deficiency, haemodialysis or peritoneal dialysis is necessary.

5. Pharmacological properties

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Drugs for acid related disorders; Antacids with antiflatulents, ATC Code: A02AF02

Dried aluminium hydroxide gel - antacid

Magnesium Hydroxide - antacid

Simeticone - antifoaming agent/antiflatulent

Pepgel Plus is a balanced mixture of two antacids and an antiflatulent/antifoaming agent simeticone. The two antacids are magnesium hydroxide which is fast acting and aluminium hydroxide which is a slow acting antacid. The combination produces a fast onset of action and an increase in total buffering time. Aluminium hydroxide on its own is an astringent and may cause constipation. This effect is balanced by the effect of the magnesium hydroxide which is in common with other magnesium salts may cause diarrhoea.

5.2 Pharmacokinetic properties

None stated.

5.3 Preclinical safety data

There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SmPC.

6. Pharmaceutical particulars

6.1 List of excipients

Sorbitol Solution 70% (non-Crystallizing)

Sodium Methyl Paraben

Sodium Propyl Paraben

Sodium Benzoate

Xanthan Gum (Pharma Grade)

Glycerol

Colloidal Anhydrous Silica

Polysorbate 80

Sodium Saccharin

Citric Acid Mononitrate

Peppermint Flavour

Erythrosine Supra
Sodium Citrate
Sodium CMC
Sucralose
Purified Water

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

36 Months

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

1 x 200ml PET bottle covering with Aluminium cap packed in primary carton along with pack insert.

6.6 Special precautions for disposal and other handling

No special requirements for disposal.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. Marketing Authorization Holder and Manufacturing Site Addresses

Marketing Authorization

Signature Healthcare Limited.

The Eco green Business Center (Tilisi)

Off A104 Nairobi -Nakuru Highway Ngecha Chunga Mali Road

P.O. Box 66172-00800, Nairobi.

MANUFACTURING SITE

Trident Lifeline Limited

Plot No. 4240, Road No. 42, GIDC, SACHIN, SURAT-394230.

GUJARAT, India

8. Marketing authorization number

CTD13544

9. Date of first registration

09/07/2026

10. Date of revision of the text

09/07/2026